Advanced search
Publication Cover
OncoImmunology Volume 8, 2019 - Issue 9
Submit an article Journal homepage
3,292
Views
18
CrossRef citations to date
0
Altmetric
Original Research

Immunological monitoring of newly diagnosed CML patients treated with bosutinib or imatinib first-line

Anna KreutzmanHematology Research Unit Helsinki, University of Helsinki and Department of Hematology, Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland;Department of Clinical Chemistry, University of Helsinki, Helsinki, FinlandCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-5587-8844View further author information
ORCID Icon,
Bhagwan YadavHematology Research Unit Helsinki, University of Helsinki and Department of Hematology, Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland;Department of Clinical Chemistry, University of Helsinki, Helsinki, FinlandView further author information
,
Tim H. BrummendorfDepartment of Hematology and Oncology, Universitätsklinikum RWTH Aachen, Aachen, GermanyView further author information
,
Bjorn Tore GjertsenDepartment of Internal Medicine, Hematology Section, Haukeland University Hospital and Department of Clinical Science, University of Bergen, Bergen, NorwayView further author information
,
Moon Hee LeeHematology Research Unit Helsinki, University of Helsinki and Department of Hematology, Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland;Department of Clinical Chemistry, University of Helsinki, Helsinki, FinlandView further author information
,
Jeroen JanssenDepartment of Hematology, VU University Medical Center, Amsterdam, The NetherlandsView further author information
,
Tiina KasanenHematology Research Unit Helsinki, University of Helsinki and Department of Hematology, Helsinki University Hospital Comprehensive Cancer Center, Helsinki, FinlandView further author information
,
Perttu KoskenvesaHematology Research Unit Helsinki, University of Helsinki and Department of Hematology, Helsinki University Hospital Comprehensive Cancer Center, Helsinki, FinlandView further author information
,
Kourosh LotfiDepartment of Medical and Health Sciences, Linköping University, Department of Hematology, County Council of Östergötland, Linköping, SwedenView further author information
,
Berit MarkevärnDepartment of Hematology, Umeå University Hospital, Umeå, SwedenView further author information
,
Ulla Olsson-StrömbergDepartment of Medical Sciences, Uppsala University and Hematology Section, Uppsala University Hospital, Uppsala, SwedenView further author information
,
Jesper StentoftDepartment of Hematology, Aarhus University Hospital, Aarhus, DenmarkView further author information
,
Leif StenkeDepartment of Hematology, Karolinska University Hospital and Karolinska Institutet, Stockholm, SwedenView further author information
,
Stina SöderlundDepartment of Medical Sciences, Uppsala University and Hematology Section, Uppsala University Hospital, Uppsala, SwedenView further author information
,
Lene UdbyDepartment of Hematology, Zealand University Hospital, Roskilde, DenmarkView further author information
,
Johan RichterDepartment of Hematology, Skåne University Hospital, Lund, SwedenView further author information
,
Henrik Hjorth-HansenDepartment of Hematology, St Olavs Hospital, Trondheim, Norway;Department of Clinical and Molecular Medicine (IKOM), Norwegian University of Science and Technology (NTNU), Trondheim, NorwayView further author information
&
Satu MustjokiHematology Research Unit Helsinki, University of Helsinki and Department of Hematology, Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland;Department of Clinical Chemistry, University of Helsinki, Helsinki, FinlandCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-0816-8241View further author information
ORCID Icon show all
Article: e1638210 | Received 03 Jan 2019, Accepted 25 Jun 2019, Published online: 13 Jul 2019

Citations (18)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Adriana Petrazzuolo, M. Chiara Maiuri, Laurence Zitvogel, Guido Kroemer & Oliver Kepp. (2022) Trial Watch: combination of tyrosine kinase inhibitors (TKIs) and immunotherapy. OncoImmunology 11:1.
Read now
Lulu Wang, Li Li, Rongrong Chen, Xianbo Huang & Xiujin Ye. (2021) Understanding and Monitoring Chronic Myeloid Leukemia Blast Crisis: How to Better Manage Patients. Cancer Management and Research 13, pages 4987-5000.
Read now

Articles from other publishers (16)

Jani Huuhtanen, Shady Adnan-Awad, Jason Theodoropoulos, Sofia Forstén, Rebecca Warfvinge, Olli Dufva, Jonas Bouhlal, Parashar Dhapola, Hanna Duàn, Essi Laajala, Tiina Kasanen, Jay Klievink, Mette Ilander, Taina Jaatinen, Ulla Olsson-Strömberg, Henrik Hjorth-Hansen, Andreas Burchert, Göran Karlsson, Anna Kreutzman, Harri Lähdesmäki & Satu Mustjoki. (2023) Single-cell analysis of immune recognition in chronic myeloid leukemia patients following tyrosine kinase inhibitor discontinuation. Leukemia.
Crossref
Inge G.P. Geelen, Stein-Erik Gullaksen, Mette M. Ilander, Ulla Olssen-Strömberg, Satu Mustjoki, Johan Richter, Nicole M.A. Blijlevens, Willem M. Smit, Bjorn T. Gjertsen, Tobias Gedde-Dahl, Berit Markevärn, Malika M.A. Koppes, Peter E. Westerweel, Henrik Hjorth-Hansen & Jeroen J.W.M. Janssen. (2023) Switching from imatinib to nilotinib plus pegylated interferon-α2b in chronic phase CML failing to achieve deep molecular response: clinical and immunological effects. Annals of Hematology 102:6, pages 1395-1408.
Crossref
Ivan Pasic, Annie H. Ren, Ram Vasudevan Nampoothiri, Ioannis Prassas, Jeffrey H. Lipton, Jonas Mattsson, Eleftherios P. Diamandis & Fotios V. Michelis. (2023) Multiplex proteomics using proximity extension assay for the identification of protein biomarkers predictive of acute graft-vs.-host disease in allogeneic hematopoietic cell transplantation. Clinical Chemistry and Laboratory Medicine (CCLM) 61:6, pages 1005-1014.
Crossref
Raffaella Pasquale, Cristina Bucelli, Valentina Bellani, Manuela Zappa, Alessandra Iurlo & Daniele Cattaneo. (2022) Case report: Pleural effusion during tyrosine-kinase inhibitor treatment in chronic myeloid leukemia: Not only a dasatinib-related adverse event. Frontiers in Oncology 12.
Crossref
Jani Huuhtanen, Mette Ilander, Bhagwan Yadav, Olli M.J. Dufva, Hanna Lähteenmäki, Tiina Kasanen, Jay Klievink, Ulla Olsson-Strömberg, Jesper Stentoft, Johan Richter, Perttu Koskenvesa, Martin Höglund, Stina Söderlund, Arta Dreimane, Kimmo Porkka, Tobias Gedde-Dahl, Björn T. Gjertsen, Leif Stenke, Kristina Myhr-Eriksson, Berit Markevärn, Anna Lübking, Andreja Dimitrijevic, Lene Udby, Ole Weis Bjerrum, Henrik Hjorth-Hansen & Satu Mustjoki. (2022) IFN-α with dasatinib broadens the immune repertoire in patients with chronic-phase chronic myeloid leukemia. Journal of Clinical Investigation 132:17.
Crossref
Aya Hirata, Eri Sawai, Marina Henmi, Chihiro Shibasaki, Yukihiro Mizoguchi, Kenta Narumi & Kazunori Aoki. (2022) Imatinib Mesylate Exerted Antitumor Effect by Promoting Infiltration of Effector T Cells in Tumor. Biological and Pharmaceutical Bulletin 45:1, pages 34-41.
Crossref
Yu-Cheng Chang, Yi-Hao Chiang, Kate Hsu, Chih-Kuang Chuang, Chen-Wei Kao, Yi-Fang Chang, Ming-Chih Chang, Ken-Hong Lim, Hung-I Cheng, Yen-Ning Hsu & Caleb G. Chen. (2021) Activated naïve γδ T cells accelerate deep molecular response to BCR-ABL inhibitors in patients with chronic myeloid leukemia. Blood Cancer Journal 11:11.
Crossref
Maiko Matsushita. (2021) Novel Treatment Strategies Utilizing Immune Reactions against Chronic Myelogenous Leukemia Stem Cells. Cancers 13:21, pages 5435.
Crossref
Alinda G. Vos, Caitlin N. Dodd, Eveline M. Delemarre, Stefan Nierkens, Celicia Serenata, Diederick E. Grobbee, Kerstin Klipstein-Grobusch & W. D. Francois Venter. (2021) Patterns of Immune Activation in HIV and Non HIV Subjects and Its Relation to Cardiovascular Disease Risk. Frontiers in Immunology 12.
Crossref
Charles Chuah, Liang Piu Koh, Tontanai Numbenjapon, Dae Young Zang, Kiat Hoe Ong, Young Rok Do, Masayuki Ohkura, Chiho Ono, Andrea Viqueira, Jorge E. Cortes & Tim H. Brümmendorf. (2021) Efficacy and safety of bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia in the Asian subpopulation of the phase 3 BFORE trial. International Journal of Hematology 114:1, pages 65-78.
Crossref
Jorge E. Cortes, Hagop M. Kantarjian, Michael J. Mauro, Fiona An, Sonja Nick, Eric Leip, Carlo Gambacorti‐Passerini & Tim H. Brümmendorf. (2021) Long‐term cardiac, vascular, hypertension, and effusion safety of bosutinib in patients with Philadelphia chromosome–positive leukemia resistant or intolerant to prior therapy. European Journal of Haematology 106:6, pages 808-820.
Crossref
Ya-Ching Hsieh, Kristina Kirschner & Mhairi Copland. (2021) Improving outcomes in chronic myeloid leukemia through harnessing the immunological landscape. Leukemia 35:5, pages 1229-1242.
Crossref
Hiroshi Ureshino. (2021) Treatment-free remission and immunity in chronic myeloid leukemia. International Journal of Hematology 113:5, pages 642-647.
Crossref
Elisa C. Toffoli, Abdolkarim Sheikhi, Yannick D. Höppner, Pita de Kok, Mahsa Yazdanpanah-Samani, Jan Spanholtz, Henk M. W. Verheul, Hans J. van der Vliet & Tanja D. de Gruijl. (2021) Natural Killer Cells and Anti-Cancer Therapies: Reciprocal Effects on Immune Function and Therapeutic Response. Cancers 13:4, pages 711.
Crossref
Martina Crysandt. (2020) Therapieadhärenz und Therapieabsetzen bei Patienten mit CML. InFo Hämatologie + Onkologie 23:5, pages 10-13.
Crossref
Hiroshi Ureshino, Takero Shindo & Shinya Kimura. (2020) Role of cancer immunology in chronic myelogenous leukemia. Leukemia Research 88, pages 106273.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.